Thursday, 2 July 2015

Patients with Lowest BMI Have Shortest Survival in Pooled Analysis of Bevacizumab in Metastatic Colorectal Cancer

Patients with the lowest body mass index (BMI) had the shortest overall survival in an analysis of bevacizumab studies in metastatic colorectal cancer (mCRC) presented for the first time today (1 July 2015) at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona. Read more here.

No comments:

Post a Comment